Appropriate invasive and conservative treatment approaches for patients with ST-Elevation MI

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochianasi nell’Infarto Miocardico (GISSI) [no authors listed]. Lancet 1986, 1:397–402. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group [no authors listed]. Lancet 1988, 2:349–360. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. The TIMI Study Group [no authors listed]. N Engl J Med 1985, 312:932–936. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators [no authors listed]. N Engl J Med 1993, 329:673–682. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators [no authors listed]. N Engl J Med 1993, 329:1615–1622. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators [no authors listed]. N Engl J Med 1997, 337:1118–1123. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators [no authors listed]. Lancet 1999, 354:716–722. Antman EM, Giugliano RP, Gibson CM, et al.: Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999, 99:2720–2732. Giugliano RP, Roe MT, Harrington RA, et al.: Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 2003, 41:1251–1260. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group [no authors listed]. Circulation 2000, 101:2788–2794. Brener SJ, Zeymer U, Adgey AA, et al.: Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002, 39:377–386. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. The GUSTO V Investigators [no authors listed]. Lancet 2001, 357:1905–1914. A randomized open-label trial comparing reteplase alone with half-dose reteplase and abciximab. Combination therapy was found to be noninferior but not superior to reteplase alone with an increased risk of noncerebral bleeding. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators [no authors listed]. Lancet 2001, 358:605–613. A randomized open-label trial comparing tenecteplase with enoxaparin or abciximab with tenecteplase and UFH. The combination of tenecteplase and enoxaparin or abciximab resulted in fewer ischemic complications. SabatineMS, Cannon CP, Gibson CM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179–1189. This study demonstrates improved infarct-related artery patency and improved clinical outcomes when clopidogrel is added to thrombolytic therapy. Chen ZM, Jiang LX, Chen YP, et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005, 366:1607–1621. Hsia J, Hamilton WP, Kleiman N, et al.: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue-plasminogen activator for acute myocardial infarction. N Engl J Med 1990, 323:1433–1437. Antman EM, Louwerenburg HW, Baars HF, et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIREThrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002, 105:1642–1649. [Published erratum appears in Circulation 2002, 105:2799.]. Wallentin L, Goldstein P, Armstrong PW, et al.: Efficacy and safety of tenecteplase in combination with the lowmolecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135–142. The combination of fibrinolytic with LMWH was shown to reduce ischemic complications compared with UFH but resulted in an increased rate of ICH in the elderly. Yusuf S, Mehta SR, Xie C, et al.: Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005, 293:427–435. A randomized trial comparing the LMWH reviparin to placebo that showed a reduced risk of death or reinfarction with reviparin with a small absolute increased risk of major bleeding. Antman EM, Morrow DA, McCabe CH, et al.: Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST elevation MI: design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI 25). Am Heart J 2005, 149:217–226. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators [no authors listed]. Lancet 2001, 358:1855–1863. Coussement PK, Bassand JP, Convens C, et al.: A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001, 22:1716–1724. Smalling RW, Bode C, Kalbfleisch J, et al.: More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995, 91:2725–2732. Grines CL, Browne KF, Marco J, et al.: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993, 328:673–679. Zijlstra F, de Boer MJ, Hoorntje JC, et al.: A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993, 328:680–684. Gibbons RJ, Holmes DR, Reeder GS, et al.: Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993, 328:685–691. Grines C, Patel A, Zijlstra F, et al.: Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003, 145:47–57. Grines CL, Cox DA, Stone GW, et al.: Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999, 341:1949–1956. Stone GW, Grines CL, Cox DA, et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957–966. Zhu MM, Feit A, Chadow H, et al.: Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001, 88:297–301. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20. A meta-analysis of 23 randomized trials that showed primary PCI to be more effective than fibrinolysis in the treatment of STEMI. AndersenHR, Nielsen TT, Rasmussen K, et al.: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003, 349:733–742. The DANAMI-2 investigators demonstrated that the strategy of hospital transfer for primary PCI is superior to on-site fibrinolysis if transfer time is less than 2 hours. Widimsky P, Budesinsky T, Vorac D, et al.: Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J 2003, 24:94–104. Nallamothu BK, Bates ER, Herrin J, et al.: Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005, 111:761–767. Cannon CP, Gibson CM, Lambrew CT, et al.: Relationship of symptom-onset-to-balloon time and door-toballoon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000, 283:2941–2947. A prospective observational study that demonstrated a significant relationship between mortality and door-to-balloon times longer than 2 hours. Berger PB, Ellis SG, Holmes DR Jr, et al.: Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999, 100:14–20. Morrison LJ, Verbeek PR, McDonald AC, et al.: Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000, 283:2686–2692. A pooled analysis of six randomized trials that demonstrated decreased all-cause hospital mortality with prehospital fibrinolysis compared with in-hospital fibrinolysis. Steg PG, Bonnefoy E, Chabaud S, et al.: Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003, 108:2851–2856. CAPTIM was a randomized trial comparing prehospital fibrinolysis to transfer for primary PCI. Patients randomized less than 2 hours from symptom onset showed a strong trend toward lower 30-day mortality if randomized to prehospital fibrinolysis. Ross AM, Coyne KS, Reiner JS, et al.: A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999, 34:1954–1962. Aviles F: GRACIA-2. Paper presented at the European Society of Cardiology Congress. Vienna, Austria; August 30 to September 3, 2003. Montalescot G, Borentain M, Payot L, et al.: Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a metaanalysis. JAMA 2004, 292:362–366. A meta-analysis of six randomized trials that showed early administration of GP IIb/IIIa inhibitors improves vessel patency with a trend toward improved clinical outcomes. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004, 110:e82-e292.